7 completed, 1 recruiting, 1 terminated. 4 Phase 3, 2 Phase 2, 2 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow secnidazole: new trials by email Literature Review of secnidazole trials Research Report on secnidazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole Metronidazole 500 mg, Secnidazole 2000 MG - Trichomonas Vaginitis, Bacterial Vaginitis | Phase 4 | Recruiting | Tulane University | 1200 | 2025-05-06 | 2026-05-06 |
| A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis Secnidazole, Placebo - Trichomonas Infection | Phase 3 | Completed | Lupin Research Inc | 147 | 2019-04-23 | 2023-10-04 |
| Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV Secnidazole - Bacterial Vaginoses | Phase 4 | Completed | Lupin Research Inc | 40 | 2018-11-28 | 2020-12-19 |
| Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219 SYM-1219 - Bacterial Vaginosis | Phase 3 | Completed | Symbiomix Therapeutics | 325 | 2015-06-01 | 2021-04-13 |
| A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis SYM-1219, Placebo - Bacterial Vaginosis | Phase 2 | Completed | Symbiomix Therapeutics | 215 | 2014-05-01 | 2020-11-13 |
| Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Fluconazole and Secnidazole - Vaginal Discharge | Phase 3 | Completed | Universidad Nacional de Colombia | 118 | 2012-05-01 | 2014-04-11 |
| A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults Secnidazole, ciprofloxacine, Amoxicillin-Clavulanic Acid - Diverticular Sigmoïditis | Phase 3 | Terminated | Quanta Medical | 100 | 2010-05-01 | 2018-09-17 |
| Studies of Immune Responses to Orally Administered Vaccines in Developing Country Placebo, Control, Zinc Sulphate - Cholera, Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 1016 | 2008-02-01 | 2011-07-12 |
| Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh Anti-Giardia and antihelmintic treatment (secnidazole or albendazole), Anti-Giardia treatment only (secnidazole or albendazole), Control group (placebo) - Giardiasis | Not applicable | Completed | University of Cambridge | 410 | 2003-06-01 | 2008-02-05 |
Vaginosis, Bacterial (4) · Vaginal Discharge (2) · Candidiasis (1) · Cholera (1) · Giardiasis (1) · Trichomonas Infections (1) · Trichomonas Vaginitis (1) · Typhoid Fever (1) · Vaginal Diseases (1)
Lupin Research Inc (2) · Symbiomix Therapeutics (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Quanta Medical (1) · Tulane University (1) · Universidad Nacional de Colombia (1) · University of Cambridge (1)
United States (5) · Bangladesh (2) · Colombia (1)
Andrea E Rodriguez, MD, MsC (1) · Ariel I Ruiz, MD, MsC (1) · Edith Muller, M.D (1) · Firdausi Qadri, PhD (1) · Jackie Shaw (1) · Jorge A Rubio, M.D., MsC (1) · Nicholas C Mascie-Taylor, ScD (1) · Patricia Kissinger, PhD (1)
PMID 18789466, PMID 28697102, PMID 33768237, PMID 37550019, PMID 42031495